Research Excellence Award

Chuang-Wei Wang is a Taiwanese pharmacology researcher and associate researcher affiliated with the Department of Medical Research at Chang Gung Memorial Hospital, Linkou. His scholarly work primarily focuses on healthcare data analysis, pharmacogenomics, drug hypersensitivity, immunotherapy, and skin immunology, with particular emphasis on severe cutaneous adverse reactions and translational immunological research.[1] Wang has contributed extensively to the identification of genetic biomarkers associated with adverse drug reactions and immune-mediated disorders, leading to significant advancements in clinical precision medicine and pharmacovigilance research.[2]

Abstract

The academic contributions of Chuang-Wei Wang reflect an interdisciplinary integration of healthcare data analysis, pharmacogenomics, dermatological immunology, and translational medicine. His research portfolio demonstrates consistent scholarly productivity in high-impact journals, particularly in studies involving severe cutaneous adverse reactions, HLA-associated drug hypersensitivity, immune checkpoint inhibitor toxicity, and immunological mechanisms underlying dermatological disorders.[3] Wang’s investigations have supported advancements in precision medicine by identifying clinically actionable biomarkers and developing predictive approaches for adverse drug reactions across Asian populations.[4]

Keywords

Healthcare Data Analysis; Pharmacogenomics; Drug Hypersensitivity; Immunotherapy; Skin Immunology; Precision Medicine; Stevens-Johnson Syndrome; Toxic Epidermal Necrolysis; HLA Biomarkers; Translational Medicine.

Introduction

Modern healthcare analytics increasingly depends on the integration of genomic profiling, immunological characterization, and large-scale clinical data interpretation. Within this context, Chuang-Wei Wang has contributed to advancing translational healthcare research through multidisciplinary studies involving immune-mediated drug reactions and precision therapeutic interventions.[5] His work has addressed clinically significant conditions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and severe hypersensitivity syndromes, providing molecular and immunological insights relevant to clinical diagnostics and personalized treatment strategies.[6]

Wang’s academic training includes doctoral research in pharmacology at National Yang-Ming University, Taiwan, combined with subsequent postdoctoral appointments and research leadership roles at Chang Gung Memorial Hospital. His research activities are characterized by collaborations across immunology, dermatology, pharmacology, and oncology disciplines.[7]

Research Profile

Chuang-Wei Wang currently serves as Associate Researcher at the Cancer Vaccine and Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Linkou, Taiwan.[8] He additionally holds an adjunct academic appointment within the Department of Physiology and Pharmacology at Chang Gung University. His research profile encompasses pharmacogenomics, adverse drug reactions, immune checkpoint inhibitor complications, and T-cell mediated immune responses.[9]

The researcher has authored or co-authored numerous publications indexed in international scientific databases, including Scopus and Web of Science. His studies frequently involve genomic analysis, HLA allele association studies, translational immunology, and clinical outcome modeling for severe dermatological conditions.[10] Wang has also participated in international conferences and scientific symposia as an invited speaker and has contributed to editorial and peer-review activities for immunology and pharmacology journals.[11]

Research Contributions

A major aspect of Wang’s scientific contributions involves identifying genetic susceptibility markers associated with severe adverse drug reactions. His studies on HLA alleles and hypersensitivity syndromes have provided clinically applicable evidence supporting genomic screening for safer therapeutic interventions.[12] Research concerning HLA-B*13:01, HLA-B*58:01, and other immunogenetic markers has influenced clinical pharmacogenomic implementation strategies across Asian populations.[13]

Wang has also contributed to immunological mechanism studies involving cytokine pathways, T-cell receptor signaling, immune checkpoint inhibitor reactions, and JAK/STAT signaling processes.[14] Several publications demonstrate translational integration between laboratory immunology and clinical therapeutic applications, particularly in the management of Stevens-Johnson syndrome and toxic epidermal necrolysis.[15]

Another notable contribution includes randomized and observational therapeutic studies evaluating TNF-α antagonists and immune-targeted therapies for severe cutaneous adverse reactions.[16] These investigations supported improved understanding of immune-mediated disease progression and therapeutic intervention outcomes within precision healthcare contexts.

Publications

Wang’s publication record includes articles published in high-impact journals such as Nature Communications, Journal of Allergy and Clinical Immunology, Clinical Pharmacology & Therapeutics, Journal of Investigative Dermatology, and British Journal of Dermatology.[17] Representative publications include studies on immune checkpoint inhibitor-induced epidermal necrolysis, pharmacogenomic screening strategies, whole genome sequencing of hypersensitivity reactions, and translational dermatological immunology.[18]

• • Hsin‐Han Hou, Yen‐Fu Chen, Yi‐Wen Chen, Chung‐Wei Wang, Shih‐Jung Cheng, et al. “Porphyromonas gingivalis and Scardovia wiggsiae promote neutrophil‐induced lung epithelial cell apoptosis and emphysema.” Journal of Periodontology, 2026.[13]
  • Hung-Chih Hsu, Hsin-Yu Chung, Jeng-Fu You, Yun-Shien Lee, Jeng-Shou Chang, Hsin-Han Hou, Chuang-Wei Wang. “Expression of Bacillus in colorectal tissues is associated with improved cetuximab therapy for patients with metastatic colorectal cancer.” Translational Oncology, 2026.[14]
  • Hu, Jie; Wang, Chuang-Wei; Li, Zheng-Rong, Zeng, Han, Lei, Yi-Cong, Tang, Zheng-Hua. “A Study on the Corrosion Behavior of Ti-Containing Weathering Steel in a Simulated Marine Environment.” Metallurgical and Materials Transactions A, 2024.[15]
  • Wang, C. W., et al. “An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice.” Frontiers in Pharmacology, 2022.[16]
  • Wang, C. W., Chung, W. H., & Hung, S. I. “Advances in the Pathomechanisms of Delayed Drug Hypersensitivity.” Immunology and Allergy Clinics of North America, 2022 [5]

Research Impact

The research impact of Chuang-Wei Wang is reflected through sustained publication activity, citation performance, and translational clinical relevance. According to available Scopus metrics, the researcher has produced 85 indexed publications with more than 2,400 citations and an h-index of 26, indicating substantial influence within immunology, dermatology, and pharmacogenomics research domains.[19]

Wang’s studies have contributed to clinical guideline development and risk stratification models involving drug hypersensitivity prediction and genomic screening implementation.[20] His research findings are particularly relevant to Asian pharmacogenomic populations and continue to support healthcare decision-making processes in adverse drug reaction prevention strategies.

In addition to publication influence, Wang has received multiple scientific recognitions, including Outstanding Paper Awards, innovation awards, and international conference invitations, further demonstrating professional recognition within biomedical research communities.

Award Suitability

The scholarly profile of Chuang-Wei Wang demonstrates strong alignment with the objectives of the Research Excellence Award in Healthcare Data Analysis. His interdisciplinary contributions integrate genomic analytics, immunological investigation, translational therapeutics, and evidence-based healthcare methodologies.The combination of high-impact publications, clinical translational outcomes, international collaboration, and measurable citation performance supports his suitability for academic recognition within healthcare analytics and biomedical research fields.

Particularly significant is Wang’s contribution to pharmacogenomic implementation and precision medicine strategies for severe adverse drug reactions. These studies have practical implications for patient safety, predictive medicine, and personalized therapeutic interventions. The translational relevance of his work extends across immunology, dermatology, oncology, and clinical pharmacology disciplines.

Conclusion

Chuang-Wei Wang has established a notable academic and translational research profile within healthcare data analysis and immunopharmacology. Through extensive investigations into pharmacogenomics, immune-mediated hypersensitivity, and translational dermatology, he has contributed to advancing precision medicine and patient safety initiatives. His publication record, citation performance, collaborative research activities, and clinical translational impact collectively support recognition within international research excellence frameworks and healthcare innovation initiatives.

External Links

• • • ORCID Profile
      
    • Scopus Author Profile
      
    • Representative DOI Publication
      
    • Award Website
      

References

• • 1. Elsevier. (n.d.). Scopus author details: Chuang-Wei Wang, Author ID 55939100300.
       https://www.scopus.com/authid/detail.uri?authorId=55939100300
       
    2. Wang, C. W., et al. (2024). Immune checkpoint inhibitor–induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade. Nature Communications.
       https://doi.org/10.1038/s41467-024-54180-7
       
    3. Wang, C. W., et al. (2021). Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians. Journal of Allergy and Clinical Immunology.
       https://doi.org/10.1016/j.jaci.2020.08.003
       
    4. Wang, C. W., Chung, W. H., & Hung, S. I. (2022). Advances in the Pathomechanisms of Delayed Drug Hypersensitivity. Immunology and Allergy Clinics of North America.
       https://doi.org/10.1016/j.iac.2022.01.009
       
    5. Lin, C. C., Chen, C. B., Wang, C. W., Hung, S. I., & Chung, W. H. (2020). Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies.
       https://doi.org/10.1080/1744666X.2020.1740591
       
    6. Wang, C. W., et al. (2022). An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice.
       https://doi.org/10.3389/fphar.2022.886377
       
    7. Pan, R. Y., Chu, M. T., Wang, C. W., et al. (2019). Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Nature Communications.
       https://doi.org/10.1038/s41467-019-11396-2
       
    8. Frontiers in Immunology Editorial Board. (2024). Reviewer and editorial activities.
       https://www.frontiersin.org/journals/immunology
       
    9. Mockenhaupt, M., Wang, C. W., Hung, S. I., et al. (2019). HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans. Allergy.
       https://doi.org/10.1111/all.13821
       
    10. Ng, C. Y., Yeh, Y. T., Wang, C. W., et al. (2016). Impact of the HLA-B*58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions.
        https://doi.org/10.1016/j.jid.2016.02.808
        
    11. Chung, H. Y., Chen, C. B., Lee, H. E., Lu, C. W., Wang, C. W., & Chung, W. H. (2025). JAK/STAT signalling pathway is involved in the immune mechanism of Bullous pemphigoid.
        https://doi.org/10.1093/bjd/ljaf219
        
    12. Chen, C. B., Hung, S. I., Chang, J. W. C., et al. (2024). Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10.
        https://doi.org/10.1038/s41467-024-54180-7
        
    13. Wang, C. W., Yang, L. Y., Chen, C. B., et al. (2018). Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation.
        https://doi.org/10.1172/JCI93349
        
    14. Journal of Allergy and Clinical Immunology. (2021). Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians.
        https://doi.org/10.1016/j.jaci.2020.08.003
        
    15. Elsevier Scopus. (2026). Author metrics and citation indicators for Chuang-Wei Wang.
        https://www.scopus.com/authid/detail.uri?authorId=55939100300
        
    16. Su, S. C., Chen, C. B., Chang, W. C., et al. (2019). HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians.
        https://doi.org/10.1002/cpt.1190
        
    17. Wang, C. W., et al. (2026). HLA-B alleles confer susceptibility to sulfasalazine-induced severe cutaneous adverse reactions. Journal of Allergy and Clinical Immunology.
        https://doi.org/10.1016/j.jaci.2026.04.017
        
    18. Research Data Analysis Excellence & Awards. (2026). Research Excellence Award criteria and recognition framework.  https://researchdataanalysis.com/
        
    19. Hung, S. I., Preclaro, I. A. C., Chung, W. H., & Wang, C. W. (2022). Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines.
        https://doi.org/10.3390/biomedicines10061260
        
    20. Wang, C. W., Dao, R. L., & Chung, W. H. (2016). Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions.
        https://doi.org/10.1097/aci.0000000000000286